Erasca
potential for rapid market entry and multiple ways to benefit patients with ras driven tumors | Erasca
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
12 of 41
Related slides by other companies
Mink Therapeutics
Investor Day
November 2022
| Mink Therapeutics
Nuvalent
Investor Presentation
October 2023
for positive advanced and other solid tumors resistance mutations | Nuvalent
Kymera
Investor Day
December 2021
degrader first in class opportunity to address driven pathology across diverse indications first degrader against an undrugged target in the clinic profound single agent activity in liquid tumor and promising activity with anti in liquid and solid tumors clinical development strategy includes direct registrational path in pathway activated heme malignancies opportunity for expansion into solid tumors in combination with immune inhibitors | Kymera
Recursion Pharmaceuticals
Investor Day
January 2023
clinical well understood clinical safety with a drug like profile further confidence prior studies suggestive of potential therapeutic benefit | Recursion Pharmaceuticals
Other recent decks by Erasca
See all presentations (4 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
IPO
July 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io